Pharming strikes second Asian deal for Ruconest
This article was originally published in Scrip
Executive Summary
Pharming Group has struck its second Asian licensing agreement for Ruconest (conestat alfa), this time with Hyupjin Corp for the development and commercialisation of the recombinant human protein C1 inhibitor in South Korea.